Disclosed is the use of N4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the manufacture of a medicament for treating local or metastatic brain cancer that is caused by ErbB2 over-expression or amplification, wherein the medicament comprises an amorphous solid dispersion comprising amorphous N4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, and wherein the amorphous solid dispersion is used after previous treatment for breast or brain cancer.
